Clinical Research Directory

Inclusion Criteria: * Participants able to give signed informed consent and assent form for adolescents, which includes willingness to comply with the schedule of follow-up visits and other requirements and restrictions listed in the informed consent form (ICF) and in this protocol * All sexes * 11 years of age or older at the start of the study and weight ≥30 kg at the screening of Part B * Participants who are CATT test or HAT RDT positive (information provided by the mobile team and included into TrypElim (see Part A) * Participants who are able to ingest oral tablets * Participants with known address and/or contact details provided * Participants who are able to comply with the schedule of follow-up visits and other requirements of the study * Participants must agree not take part in any other clinical trials during the participation in part B of this study * Participants of child-bearing potential must be willing to use appropriate contraceptive methods. Exclusion Criteria: * Individuals with a positive parasitological exam on the spot at baseline (mAECT or lymph gland puncture) * Participants previously treated for g-HAT or previously treated because of gHAT seropositive results * Pregnant women * Breast-feeding women * Children ≥11 years, but under 30kg body weight at the screening for part B * Clinically significant medical condition that could, in the opinion of the investigator, jeopardise the subject's safety or participation in the study * Individuals presenting a jaundice at screening * Participants who are taking, or who are expected to need to start within 3 months, a medicine (including traditional or herbal) which may interact with acoziborole and which cannot be stopped or adjusted (please refer to investigator manual or contact DNDi)